MedDataX Logo

Physiologic Performance Response to Salbutamol

NCT ID: NCT04615611

Last Updated: 2020-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-07

Study Completion Date

2021-11-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project aims to investigate the individual physiological response to beta2-adrenergic stimulation with salbutamol on performance-related outcomes

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

salbutamol

salbutamol, 800 microgram from metered dose inhaler

Group Type EXPERIMENTAL

salbutamol

Intervention Type DRUG

inhalation of salbutamol

placebo

placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

administration of placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

salbutamol

inhalation of salbutamol

Intervention Type DRUG

Placebo

administration of placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 to 45 years of age
* Trained individuals with maximal oxygen uptake above 55 mL/kg/min for men and 50 mL/kg/min for women
* Body mass index lower than 26

Exclusion Criteria

* Allergy towards study drug
* Unacceptable side effects of the study drug
* Chronic disease deemed by the MD to impose a risk or severely confound the study outcomes
* Current smokers
* Use of prescription medicine
* Pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Morten Hostrup, PhD

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SAL-POWER

Identifier Type: -

Identifier Source: org_study_id